African Sleeping Sickness (Trypanosoma brucei)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
African sleeping sickness is a tsetse-fly-transmitted parasitic infection found in focal areas of sub-Saharan Africa. It first affects the blood and lymph, causing fever, headache and enlarged lymph nodes; later brain involvement can cause behavior changes, abnormal sleep and poor coordination. Gambiense disease in West/Central Africa usually progresses over months to years; rhodesiense disease in East/Southern Africa often progresses over weeks to months. Untreated infection is usually fatal. Early diagnosis and treatment can prevent severe organ and brain injury.
Clinical Definition
Human African trypanosomiasis (HAT) is caused by extracellular Trypanosoma brucei gambiense or T. b. rhodesiense, transmitted by infected Glossina (tsetse) flies. First-stage hemolymphatic disease precedes second-stage meningoencephalitis. Gambiense is generally chronic, with humans the main reservoir; rhodesiense is usually acute and zoonotic, with important animal reservoirs. T. b. brucei normally does not infect humans. Variant surface glycoprotein (VSG) switching permits antibody escape and recurrent parasitemia. Symptoms alone do not reliably establish CNS stage or severity.
Inciting Event
Bite of an infected tsetse fly introduces metacyclic trypomastigotes into the skin.
Injection of parasites during blood meal initiates systemic infection.
Parasite entry into lymphatics leads to early dissemination and lymphadenopathy.
Latency Period
Rhodesiense HAT generally becomes symptomatic within weeks of infection and can progress rapidly; severe systemic illness may precede clear neurological signs.
Gambiense HAT may remain unrecognized for months or years, with subtle or intermittent systemic symptoms before advanced disease is detected.
Progression to CNS disease is generally weeks to months in rhodesiense and months to years in gambiense; these are typical patterns, not fixed incubation or staging cutoffs.
Diagnostic Delay
Early symptoms are nonspecific and mimic common febrile illnesses, leading to misdiagnosis.
Limited access to specialized diagnostic tests such as blood smear or CSF analysis delays confirmation.
Lack of awareness in non-endemic areas causes missed diagnosis in travelers.
CNS symptoms may be attributed to other neurological diseases before considering African sleeping sickness.
Clinical Presentation
Signs & Symptoms
Intermittent fever and generalized malaise are early systemic symptoms.
Posterior cervical lymphadenopathy (Winterbottom sign) is a classic clue, especially in gambiense HAT; its absence does not exclude infection.
Headache, pruritus, and joint pains frequently occur during the hemolymphatic phase.
Confusion, abnormal behavior, ataxia and other neurological abnormalities suggest CNS disease. Sleep disturbance is characteristic but does not alone establish severe second-stage disease.
Progressive somnolence and movement disorders develop in the meningoencephalitic phase.
History of Present Illness
Initial presentation includes intermittent fevers, headaches, and malaise during the hemolymphatic stage.
Ask about enlarged posterior cervical nodes (Winterbottom sign, especially gambiense), a bite-site chancre, rural exposure and travel timing.
Progression to the meningoencephalitic stage causes sleep disturbances, behavioral changes, and neurological deficits.
Daytime sleepiness and disrupted nighttime sleep are important clues; sleep changes alone do not determine CNS severity or whether lumbar puncture is required for treatment selection.
Late-stage disease includes seizures, coma, and death if untreated.
Past Medical History
Previous exposure to tsetse fly bites or residence in endemic areas increases suspicion.
History of untreated or partially treated trypanosomiasis may lead to relapse or chronic symptoms.
Review prior HAT treatment, liver/renal disease, cardiac rhythm disorders, pregnancy and current medicines, because these affect drug selection and monitoring; pre-existing immune suppression is not required for infection.
Family History
HAT is an acquired infection, not a Mendelian familial syndrome. Family clustering usually reflects shared exposure; rare maternal-fetal transmission can occur.
Family members living in the same endemic area share similar environmental exposure risks.
Host variants such as APOL1 have been associated with susceptibility or protection in some studies, but findings vary by parasite form and population. Routine genetic testing is not part of HAT diagnosis or prevention.
Physical Exam Findings
Posterior cervical lymphadenopathy (Winterbottom sign) is particularly associated with gambiense disease; examine other nodal regions as well.
Fever with intermittent spikes is commonly observed during the hemolymphatic phase.
A tender inflammatory trypanosomal chancre may occur at the bite site, particularly with rhodesiense infection; many patients have no recognized chancre.
Neurological signs such as altered mental status, somnolence, and ataxia appear in the late meningoencephalitic stage.
Tremors and abnormal sleep-wake cycles are hallmark findings in advanced disease.
Diagnostic Workup
Diagnostic Criteria
Confirm suspected HAT by demonstrating trypanosomes in blood, lymph-node or chancre material, or CSF when assessed. Gambiense serology supports screening but is not generally sufficient alone; national protocols may address selected serological suspects. For CSF staging, >5 WBC/uL OR trypanosomes indicates second stage; first stage requires ≤5 WBC/uL and no CSF parasites. Under the WHO 2024 gambiense algorithm, patients aged ≥6 years AND weighing ≥20 kg without clinical signs suggesting severe disease can receive fexinidazole without LP. If severe disease is suspected, use CSF assessment: ≥100 WBC/uL favors NECT, while <100 permits fexinidazole; unavailable/uninterpretable CSF in this setting favors NECT. Eligible rhodesiense patients can receive fexinidazole for either stage without LP for treatment choice. Newer acoziborole covers both gambiense stages in its eligible population where approved; follow the applicable national protocol.
Pathophysiology
Key Mechanisms
Trypanosoma brucei parasites evade immune clearance via antigenic variation of their variant surface glycoprotein (VSG) coat.
Parasite replication in the bloodstream and lymphatics causes systemic inflammation and tissue damage.
CNS invasion leads to meningoencephalitis with disruption of the blood-brain barrier and neuroinflammation.
Variant-specific antibodies reduce one parasite population, while VSG-switched variants can expand. Recurrent parasitemia and inflammatory responses contribute to waves of fever.
Hemolymphatic spread results in widespread organ involvement including spleen and liver enlargement.
| Involvement | Details |
|---|---|
| Organs | Lymph nodes become enlarged due to immune activation and parasite infiltration during early infection. |
Brain involvement in late-stage disease leads to characteristic neurological signs including sleep disturbances and cognitive decline. | |
The spleen participates in immune activation and removal of circulating parasites and may enlarge. T. brucei is extracellular in humans; it does not have a malaria-like infected-erythrocyte stage. | |
| Tissues | Blood is the primary tissue where trypanosomes circulate and cause hemolymphatic symptoms. |
Central nervous system tissue is invaded in late-stage disease causing meningoencephalitis and neurological symptoms. | |
| Cells | Trypanosomes are extracellular protozoan parasites responsible for infection and immune evasion. |
Macrophages contribute to parasite clearance and inflammatory signaling; antibody responses help remove parasites expressing recognized VSG variants. | |
B-cell/antibody responses target the current VSG coat; parasites expressing a different VSG can escape and expand, producing recurrent parasitemia. T-cells also regulate immunity, but VSG switching is principally an antibody-evasion concept. | |
| Chemical Mediators | TNF-alpha contributes to inflammatory responses and fever; its balance between parasite control and host injury depends on context. |
IFN-gamma activates macrophage responses. Experimental trypanosomiasis studies also implicate inflammatory signaling in CNS disease; this is not a uniform clinical biomarker pattern. | |
Activated macrophages can produce nitric oxide, with antiparasitic and immune/tissue effects demonstrated largely in experimental models. Its net contribution varies with disease context. |
Treatments
Pharmacological Treatments
Suramin
- Mechanism:
Suramin affects multiple parasite processes, including energy metabolism; its exact trypanocidal mechanism is not fully defined. It does not adequately penetrate the CNS.
- Side effects:
Hypersensitivity reactions
Nephrotoxicity
Peripheral neuropathy
- Clinical role:
Used for first-stage rhodesiense HAT when fexinidazole is unsuitable, including children <6 years OR <20 kg under WHO 2024 guidance. It is not adequate treatment for established CNS disease.
Pentamidine
- Mechanism:
Pentamidine is an aromatic diamidine affecting parasite nucleic-acid and other cellular processes; its precise antitrypanosomal mechanism is incompletely defined. CNS penetration is insufficient for definitive second-stage therapy.
- Side effects:
Hypotension and cardiac rhythm disturbances require monitoring.
Nephrotoxicity
Hypoglycemia, sometimes followed by hyperglycemia/diabetes, and pancreatitis can occur.
- Clinical role:
An option for first-stage gambiense HAT, particularly children <6 years OR <20 kg and patients unable to receive fexinidazole. It can provide interim therapy for rhodesiense disease while recommended drugs are obtained; it does not replace definitive CNS treatment.
Melarsoprol
- Mechanism:
Melarsoprol is an arsenical with effects on parasite thiol-dependent enzymes/metabolism; its actions are not confined to one target. It reaches the CNS but has substantial host toxicity.
- Side effects:
Reactive encephalopathy can be fatal; neurological deterioration during treatment requires urgent assessment and interruption of melarsoprol.
Peripheral neuropathy
Painful infusion/phlebitis, skin reactions and gastrointestinal toxicity; corticosteroid co-treatment may reduce encephalopathy risk but does not eliminate it.
- Clinical role:
Reserved principally for second-stage rhodesiense HAT when fexinidazole cannot be used, including younger/smaller children, and selected specialist rescue situations. It is no longer the universal first-line treatment for CNS HAT.
Nifurtimox-eflornithine combination therapy (NECT)
- Mechanism:
Eflornithine irreversibly inhibits ornithine decarboxylase, reducing polyamine synthesis; nifurtimox is activated by parasite nitroreductases to reactive products. NECT combines IV eflornithine with oral nifurtimox.
- Side effects:
Cytopenias/bone-marrow suppression and infection risk require monitoring.
Seizures and other neurological/psychiatric adverse effects may occur.
Nausea, vomiting, diarrhea, appetite loss and headache are important tolerability issues.
- Clinical role:
WHO 2024 first choice for severe second-stage gambiense HAT (CSF >=100 WBC/uL) and second-stage disease in children <6 years OR <20 kg; also used when fexinidazole is unsuitable. Eflornithine is not effective for rhodesiense HAT. Eflornithine alone is a fallback when NECT and fexinidazole cannot be used. Newer acoziborole availability depends on national approval/programs.
Fexinidazole
- Mechanism:
A nitroimidazole activated through parasite nitroreductase pathways to reactive metabolites that damage cellular macromolecules; the precise killing mechanism is not fully established.
- Side effects:
QT prolongation; review interacting medicines and cardiac/electrolyte risks.
Neuropsychiatric effects, neutropenia and hepatotoxicity require assessment and monitoring.
US-label contraindications include Cockayne syndrome, nitroimidazole hypersensitivity and severe hepatic impairment; avoid in severe renal impairment. Follow label restrictions on alcohol and interacting medicines.
- Clinical role:
For patients >=6 years AND >=20 kg, WHO 2024 recommends it for first-stage/nonsevere second-stage gambiense and both stages of rhodesiense HAT. Give the 10-day oral course with substantial food and supervised adherence. Severe gambiense disease generally needs NECT or another locally approved appropriate regimen. The US label covers gambiense, not rhodesiense.
Acoziborole (Acoziborole Winthrop)
- Mechanism:
A benzoxaborole thought to inhibit parasite CPSF3, disrupting messenger-RNA maturation; its mechanism is not fully characterized.
- Side effects:
QT shortening: contraindicated in familial short-QT syndrome. Fever, weakness, decreased appetite, headache and tremor can occur.
Strong CYP3A4 induction and CYP2D6 inhibition cause important interactions for up to 3 months; carry the patient card and check every concomitant medicine.
Artemether-lumefantrine is contraindicated during and for 1 month after treatment. Specified antiretroviral/anti-infective medicines and nifedipine have additional contraindications and 3-month restrictions; consult the complete product information.
Use in pregnancy only if urgent treatment is needed and no alternative exists; breastfeeding is not recommended. Avoid pregnancy for 2 months; add barrier protection to hormonal contraception for 3 months. Severe hepatic impairment is not recommended.
- Clinical role:
2026 update: received a positive EMA opinion for use outside the EU and DRC approval for gambiense HAT, including severe second-stage disease. The EMA product information covers adults and adolescents >=12 years weighing >=40 kg; the weight criterion applies to adolescents. A single oral dose is taken without food for 2 hours before and after. Use depends on national authorization and program guidance; clinical use for rhodesiense is not established.
Non-pharmacological Treatments
Supportive care including management of fever, hydration, and nutritional support is essential during treatment.
Support completion of therapy and arrange relapse surveillance for up to 24 months, tailored to the regimen and national guidance. Recurrent symptoms need prompt reassessment; routine repeated LP is not required for every patient.
Prevention
Pharmacological Prevention
There is no vaccine or recommended preventive medication for African sleeping sickness. Treatment drugs are used for infection, not routine traveler prophylaxis.
Insecticide-based vector control is a public-health measure, not a medicine taken by an exposed person.
Non-pharmacological Prevention
Avoidance of tsetse fly habitats such as dense vegetation reduces exposure risk.
Wear medium-weight, neutral-colored long clothing; tsetse flies can bite through thin fabric. Inspect vehicles and avoid disturbing bushes. Repellents and permethrin are not particularly effective against tsetse, although they may protect against other insects.
Case finding and treatment help reduce the human reservoir of gambiense HAT. Treating human rhodesiense cases does not eliminate its important animal reservoir.
Locally targeted tsetse traps and insecticide-treated targets, coordinated through control programs, reduce vector exposure. Bed nets alone are insufficient for these predominantly daytime-biting flies.
Outcome & Complications
Complications
Severe meningoencephalitis leading to coma and death if untreated.
Cardiac involvement including myocarditis and arrhythmias may occur.
Severe systemic disease can cause organ dysfunction and nutritional deterioration; rhodesiense HAT may become life-threatening before obvious CNS findings. Assess concurrent infections when clinically indicated.
Seizures and neurological deficits can result from CNS invasion.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
African Sleeping Sickness (Trypanosoma brucei) versus Malaria
African Sleeping Sickness (Trypanosoma brucei) | Malaria |
|---|---|
Tsetse exposure in focal sub-Saharan African transmission areas. | Exposure to Anopheles mosquitoes in malaria-endemic areas, including overlapping African regions. |
Extracellular trypomastigotes with a kinetoplast and flagellum; parasitemia may be low, especially in gambiense HAT. | Intraerythrocytic Plasmodium forms on blood films; the human blood-stage location contrasts with extracellular T. brucei. |
Hemolymphatic illness followed by CNS disease; gambiense is usually slower than rhodesiense. | Fever may be irregular, especially early; a 48-72-hour pattern is not required. Severe malaria can rapidly cause encephalopathy or coma. |
Demonstration of trypanosomes in blood, lymph-node/chancre material or CSF when assessed. | Thick/thin blood films identify parasites and species/parasitemia. RDTs can assist but require microscopy; repeat smears if initial tests are negative and suspicion remains high. |
African Sleeping Sickness (Trypanosoma brucei) versus Neurosyphilis
African Sleeping Sickness (Trypanosoma brucei) | Neurosyphilis |
|---|---|
Rhodesiense usually progresses over weeks/months; gambiense often evolves over months/years. | Neurosyphilis can occur at any stage: early meningitis/vascular disease or later cognitive and posterior-column syndromes. |
Parasitological confirmation plus appropriate CSF assessment; routine PCR is not a universal standard. | Integrate serum syphilis tests, neurological findings and CSF. CSF-VDRL is specific but insensitive; positive CSF FTA-ABS alone is not definitive. |
For HAT staging, CSF >5 WBC/uL OR trypanosomes supports second stage; visible parasites are not mandatory. | CSF lymphocytic pleocytosis/protein elevation may support the diagnosis but are nonspecific; negative CSF-VDRL does not exclude it. |
African Sleeping Sickness (Trypanosoma brucei) versus Viral Encephalitis (e.g., Herpes Simplex Virus)
African Sleeping Sickness (Trypanosoma brucei) | Viral Encephalitis (e.g., Herpes Simplex Virus) |
|---|---|
Systemic symptoms with variable progression to neurological/sleep abnormalities; tempo depends on subspecies. | HSV encephalitis typically presents acutely over days, with fever, altered behavior/mental status and sometimes focal seizures. |
Demonstrate trypanosomes in appropriate specimens; use the relevant CNS-stage assessment. | CSF HSV PCR supports diagnosis. An early negative result may be false negative; repeat testing when clinical suspicion remains strong. |
MRI may show nonspecific white-matter/inflammatory changes; it cannot confirm or exclude HAT. | Temporal-lobe abnormalities are characteristic but not universal; early MRI can be nondiagnostic. |
African Sleeping Sickness (Trypanosoma brucei) versus Tuberculous Meningitis
African Sleeping Sickness (Trypanosoma brucei) | Tuberculous Meningitis |
|---|---|
Exposure to infected tsetse flies in an active African focus. | TB exposure or residence in a high-incidence setting; known exposure is not required, and geography can overlap with HAT. |
CSF pleocytosis and/or trypanosomes support second stage; chemistry is not a reliable stand-alone discriminator. | Often lymphocytic pleocytosis, high protein and low glucose, but this pattern is not specific. CSF acid-fast smear has limited sensitivity. |
Parasitological confirmation with CSF examination when indicated; not every CNS case has visible CSF organisms. | CSF mycobacterial NAAT (e.g., Xpert/Ultra) and culture support confirmation. Negative tests do not rule out TB meningitis. |
African Sleeping Sickness (Trypanosoma brucei) versus Leishmaniasis (Visceral)
African Sleeping Sickness (Trypanosoma brucei) | Leishmaniasis (Visceral) |
|---|---|
Tsetse exposure in focal sub-Saharan African areas. | Sandfly exposure, including East Africa as well as South Asia and other endemic regions; geography can overlap. |
Extracellular trypomastigotes in blood or other diagnostic material. | Intracellular amastigotes in macrophages, identified in tissue such as bone marrow. Splenic aspiration can be diagnostic but has important bleeding risk. |
Hemolymphatic disease can progress to meningoencephalitis and sleep-wake disruption. | Prolonged fever, splenomegaly/hepatomegaly and pancytopenia are characteristic; CNS disease is not the typical defining syndrome. |